Darwin-T2D

Clinical characteristics of type 2 diabetic patients at the time they start Dapagliflozin in the real world. A retrospective multicenter descriptive study

Caratteristiche cliniche dei pazienti diabetici tipo 2 al momento dell’inizio della terapia con Dapagliflozin nella pratica clinica reale. Studio multicentrico retrospettivo - Darwin T2D

Pubblicazioni

• Fadini GP, Zatti G, Consoli A, Bonora E, Sesti G, Avogaro A; DARWIN-T2D Network. Rationale and design of the DARWIN-T2D (DApagliflozin Real World evIdeNce in Type 2 Diabetes): A multicenter retrospective nationwide Italian study and crowdsourcing opportunity. Nutr Metab Cardiovasc Dis. 2017 Dec;27(12):1089-1097.
• Fadini GP, Zatti G, Baldi I, Bottigliengo D, Consoli A, Giaccari A, Sesti G, Avogaro A; DARWIN-T2D network. Use and effectiveness of dapagliflozin in routine clinical practice: An Italian multicentre retrospective study. Diabetes Obes Metab. 2018 Jul;20(7):1781-1786.
• Fadini GP, Bottigliengo D, D'Angelo F, Cavalot F, Bossi AC, Zatti G, Baldi I, Avogaro A; DARWIN-T2D Network. Comparative Effectiveness of DPP-4 Inhibitors Versus Sulfonylurea for the Treatment of Type 2 Diabetes in Routine Clinical Practice: A Retrospective Multicenter Real-World Study. Diabetes Ther. 2018 Aug;9(4):1477-1490.
• Fadini GP, Solini A, Manca ML, Zatti G, Karamouzis I, Di Benedetto A, Frittitta L, Avogaro A; DARWIN-T2D Network. Phenotyping normal kidney function in elderly patients with type 2 diabetes: a cross-sectional multicentre study. Acta Diabetol. 2018 Nov;55(11):1121-1129.
• Fadini GP, Solini A, Manca ML, Penno G, Gatti A, Anichini R, Del Prato S, Avogaro A; DARWIN-T2D Network. Effectiveness of dapagliflozin versus comparators on renal endpoints in the real world: A multicentre retrospective study. Diabetes Obes Metab. 2019 Feb;21(2):252-260.
• Fadini GP, Bonora BM, Lapolla A, Fattor B, Morpurgo PS, Simioni N, Avogaro A; DARWIN-T2D Network. Comparative effectiveness of exenatide once-weekly versus liraglutide in routine clinical practice: A retrospective multicentre study and meta-analysis of observational studies. Diabetes Obes Metab. 2019 May;21(5):1255-1260.
• Fadini GP, Sciannameo V, Franzetti I, Bottigliengo D, D'Angelo P, Vinci C, Berchialla P, Arena S, Buzzetti R, Avogaro A; DARWIN-T2D network. Similar effectiveness of dapagliflozin and GLP-1 receptor agonists concerning combined endpoints in routine clinical practice: A multicentre retrospective study. Diabetes Obes Metab. 2019 Aug;21(8):1886-1894.
• Fadini GP, Li Volsi P, Devangelio E, Poli M, Cazzetta G, Felace G, Avogaro A; DARWIN-T2D Network. Predictors of early discontinuation of dapagliflozin versus other glucose-lowering medications: a retrospective multicenter real-world study. J Endocrinol Invest. 2020 Mar;43(3):329-336.
• Fadini GP, Tentolouris N, Caballero Mateos I, Bellido Castañeda V, Morales Portillo C. A Multinational Real-World Study on the Clinical Characteristics of Patients with Type 2 Diabetes Initiating Dapagliflozin in Southern Europe. Diabetes Ther. 2020 Feb;11(2):423-436.
• Sciannameo V, Fadini GP, Bottigliengo D, Avogaro A, Baldi I, Gregori D, Berchialla P. Assessment of Glucose Lowering Medications' Effectiveness for Cardiovascular Clinical Risk Management of Real-World Patients with Type 2 Diabetes: Targeted Maximum Likelihood Estimation under Model Misspecification and Missing Outcomes. Int J Environ Res Public Health. 2022 Nov 11;19(22):14825.
• Sciannameo V, Berchialla P, Avogaro A, Fadini GP; DARWIN-T2D Network. Transposition of cardiovascular outcome trial effects to the real-world population of patients with type 2 diabetes. Cardiovasc Diabetol. 2021 May 10;20(1):103.
• Morieri ML, Vitturi N, Avogaro A, Targher G, Fadini GP; DARWIN-T2D Network of the Italian Diabetes Society. Prevalence of hepatic steatosis in patients with type 2 diabetes and response to glucose-lowering treatments. A multicenter retrospective study in Italian specialist care. J Endocrinol Invest. 2021 Sep;44(9):1879-1889.
• Morieri ML, Avogaro A, Fadini GP; the DARWIN-T2D Network of the Italian Diabetes Society. Cholesterol lowering therapies and achievement of targets for primary and secondary cardiovascular prevention in type 2 diabetes: unmet needs in a large population of outpatients at specialist clinics. Cardiovasc Diabetol. 2020 Nov 10;19(1):190.
• Sciannameo V, Berchialla P, Orsi E, Lamacchia O, Morano S, Querci F, Consoli A, Avogaro A, Fadini GP; DARWIN-T2D study. Enrolment criteria for diabetes cardiovascular outcome trials do not inform on generalizability to clinical practice: The case of glucagon-like peptide-1 receptor agonists. Diabetes Obes Metab. 2020 May;22(5):817-827
• Fadini GP, Tentolouris N, Caballero Mateos I, Bellido Castañeda V, Morales Portillo C. A Multinational Real-World Study on the Clinical Characteristics of Patients with Type 2 Diabetes Initiating Dapagliflozin in Southern Europe. Diabetes Ther. 2020 Feb;11(2):423-436.